Yeh DC - Search Results

1

EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.

Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F, Kuo WH, Chang KJ, Lin YC, Tseng LM, Hou MF. Yeh DC, et al. In Vivo. 2014 Sep-Oct;28(5):1001-4. In Vivo. 2014. PMID: 25189922 Clinical Trial.

2

Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.

Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang CS. Lu YS, et al. Among authors: yeh ht, yeh dc. Cancer Chemother Pharmacol. 2011 Jun;67(6):1257-63. doi: 10.1007/s00280-010-1401-2. Epub 2010 Aug 11. Cancer Chemother Pharmacol. 2011. PMID: 20700740 Clinical Trial.

3

Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.

Chao TC, Chen DR, Chao TY, Chen SC, Yeh DC, Wang HC, Huang WT, Rau KM, Chang KJ, Yang TL, Lee KD, Tai CJ, Tseng LM, Hou MF. Chao TC, et al. Among authors: yeh dc. Anticancer Res. 2013 Dec;33(12):5543-7. Anticancer Res. 2013. PMID: 24324095

4

Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.

Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL; Taiwan Breast Cancer Consortium. Lu YS, et al. Among authors: yeh dc. Clin Cancer Res. 2015 Apr 15;21(8):1851-8. doi: 10.1158/1078-0432.CCR-14-2075. Epub 2015 Feb 19. Clin Cancer Res. 2015. PMID: 25700303 Clinical Trial.

5

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group. Harbeck N, et al. Among authors: yeh dc. Lancet Oncol. 2016 Mar;17(3):357-366. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26. Lancet Oncol. 2016. PMID: 26822398 Clinical Trial.

6

Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer.

Lee CL, Tsai CH, Yeh DC, Lin CS, Li YF, Tzeng HE. Lee CL, et al. Among authors: yeh dc. Oncotarget. 2017 Jan 3;8(1):1569-1579. doi: 10.18632/oncotarget.13679. Oncotarget. 2017. PMID: 27906669 Free PMC article.

7

A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.

Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, Hsieh YY, Huang SM, Cheng AL, Lu YS, Consortium TBC. Chen TW, et al. Among authors: yeh dc. Jpn J Clin Oncol. 2018 Mar 1;48(3):242-247. doi: 10.1093/jjco/hyx188. Jpn J Clin Oncol. 2018. PMID: 29315394 Clinical Trial.

8

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.

Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N. Im SA, et al. Among authors: yeh dc. Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4. Sci Rep. 2020. PMID: 32472001 Free PMC article. Clinical Trial.

9

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.

10

Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.

Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, Yang K, Wu HC, Chao TY, Chang YC, Lin PC, Kuo WH, Kuo WL, Lin CH, Chen HM, Yeh DC, Liu LC, Liu CY, Wang MY, Lo C, Lu YS, Huang CS. Lin PH, et al. Among authors: yeh dc. Breast Cancer Res Treat. 2022 Apr;192(3):629-637. doi: 10.1007/s10549-021-06446-7. Epub 2022 Feb 3. Breast Cancer Res Treat. 2022. PMID: 35113257

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters